Skip to main content

Table 2 Clinicopathological and genetic characteristics of Iranian CRC cases.

From: Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study

  Iranian     
  All non-MSI-H MSI-H Odds Ratio P
Number of patients 53 39 (74)a 14 (26)a   
Mean Age 59.8+12.7
-
59.9+12.7
-
59.4+13.1
-
  0.90
Gender 53     0.52
   Female 19(36) 13(33) 6(43) 1  
   Male 34(64) 26(67) 8(57) 0.67(0.19–2.33)  
Site 53     0.00
   Distal 40(76) 37(95) 3(21) 1  
   Proximal 13(24) 2(5) 11(79) 66.67(10–500.00)  
Mucin Production NA     
   None NA     
   < 50% NA     
   > 50% NA     
Differentiation 53     0.00
   Well 29(54) 26(67) 3(22) 1  
   Moderate 22(42) 13(33) 9(64) 6(1.38–26.00)  
   Poor 2(4) 0 2(14) NA  
Stage 53     0.67
   Stage 1 0 0 0 NA  
   Stage 2 12(23) 10(26) 2(14) 1  
   Stage 3 37(70) 26(67) 11(79) 0.60(0.04–9.16)  
   Stage 4 4(7) 3(7) 1(7) 1.27(0.12–13.58)  
BRAF 53     0.09
   Wild type 52(98) 39(100) 13(93)   
   V600E 1(2) 0 1(7) NA  
hMLH1 methylation (MSP) 53     0.00
   Unmethylation 42(79) 38(97) 4(29) 1  
   Methylation 11(21) 1(3) 10(71) 95.00(9.53–946.94)  
p16 methylation (MSP) 53     0.00
   Unmethylation 45(85) 38(97) 7(50) 1  
   Methylation 8(15) 1(3) 7(50) 38.00(4.03–358.74)  
hMLH1 expression by IHC 25     0.00
   Normal 15(60) 12(100) 3(23)   
   Negative 10(40) 0 10(77) NA  
hMSH2 expression by IHC 25     1.00
   Normal 24(96) 12(100) 12(92)   
   Negative 1(4) 0 1(8) NA